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OBJECTIVES We sought to make a prospective comparison of systematic stenting with provisional stenting
guided by Doppler measurements of coronary velocity reserve and quantitative coronary
angiography.
BACKGROUND Despite the increasing use of stents during percutaneous transluminal coronary angioplasty,
it is unclear whether systematic stenting is superior to a strategy of provisional stenting in
which stents are placed only in patients with unsatisfactory results or as a bail-out procedure.
METHODS Two hundred fifty-one patients undergoing elective coronary angioplasty were randomly
assigned either to provisional stenting (group 1, in which stenting was performed if
postangioplasty coronary velocity reserve was ,2.2 and/or residual stenosis $35% or as
bail-out) or to systematic stenting (group 2). The primary end point was the six-month
angiographic minimal lumen diameter (MLD). Major adverse cardiac events were secondary
end points (death, acute myocardial infarction and target lesion revascularization).
RESULTS Stenting was performed in 48.4% of patients in group 1 and 100% of patients in group 2 (p ,
0.01). Six months after angioplasty, the MLD did not differ between groups (1.90 6 0.79 mm
vs. 1.99 6 0.70 mm, p 5 0.39), as was the rate of binary restenosis (27.1% vs. 21.4%, p 5
0.37). Among patients with restenosis, 13/32 (40.6%) in group 1 but 100% (25/25) in group
2 had in-stent restenosis (p , 0.01). Target lesion revascularization (15.1% vs. 14.4% in
groups 1 and 2 respectively, p 5 0.89) and major adverse cardiac events (15.1% vs. 16.0%, p 5
0.85) were not significantly different.
CONCLUSIONS Systematic stenting does not provide superior angiographic results at six months as compared
with provisional stenting. (J Am Coll Cardiol 2000;36:404–9) © 2000 by the American
College of Cardiology
Coronary stenting is one of the major advances in percuta-
neous transluminal coronary angioplasty (PTCA), allowing
reduction of the short-term complications as well as the
incidence of restenosis (1,2). This has led to a rapid and
steep increase in the use of stents for PTCA. It remains
unclear whether stents should be systematically implanted
during PTCA or whether a strategy of “provisional stent-
ing” is acceptable, in which stents are placed in case of
unsatisfactory immediate results of balloon angioplasty.
Specifically, the benefits of stenting may be partially offset
by the high recurrence rate of in-stent restenosis when
treated by repeat percutaneous coronary intervention (3).
Conversely, the combination of quantitative coronary an-
giography (QCA) and coronary velocity reserve (CVR)
measurements after PTCA allows identification of a subset
of patients with an excellent clinical and angiographic
outcome without the need for systematic stenting (4). Thus,
the current trial sought to make a prospective comparison of
systematic stenting with a policy of provisional stenting
guided by QCA and CVR measurements with respect to
angiographic outcome and major cardiac adverse events.
METHODS
Selection of patients. The study population consisted of
patients with proven myocardial ischemia and de novo
lesions of the native coronary circulation scheduled for
PTCA of a single discrete lesion of #15 mm length and a
vessel reference diameter $2.7 mm by local QCA. Exclu-
sion criteria were age .75 years, acute myocardial infarction
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(AMI) within the previous three weeks, left ventricular
ejection fraction ,50%, total occlusion of the target vessel,
left main coronary artery stenosis $50%, abnormal wall
motion in the area of the target vessel, hypertrophic cardio-
myopathy and more than one lesion on the target vessel for
optimal interpretation of the Doppler findings (4).
Treatment groups. After providing written informed con-
sent, the patients were randomly assigned to two groups
using a sealed envelope system: in group 1 (provisional
stenting) PTCA was performed using the local routine, and
the final result was assessed by QCA and CVR measure-
ments using a Doppler wire (Flowire, Endosonics Corpo-
ration, Rancho Cordova, California). Patients in whom the
residual diameter stenosis (DS) was ,35% and CVR was
$2.2 did not undergo stent placement. The choice of CVR
$2.2 was based upon a previous pilot study (5) and is within
the range of values chosen by the Doppler End Points
Balloon Angioplasty Trial Europe (DEBATE) II and
Doppler End Point Stenting International Investigation
Coronary Flow Reserve (DESTINI) trials (2.5 and 2.0,
respectively [6,7]). Patients who failed to fulfill both of these
criteria underwent stenting. The steps taken toward im-
proving the suboptimal outcome were left to the discretion
of the operator. Additionally, patients with acute or threat-
ened closure of the target vessel received a stent as a
“bail-out” procedure. In group 2 (systematic stenting),
patients underwent balloon angioplasty followed by system-
atic stent placement using a PS-153 stent (Johnson and
Johnson Interventional Systems, Warren, New Jersey) with-
out measurement of CVR and regardless of the angio-
graphic result achieved by balloon angioplasty alone. Stents
were placed using delivery pressures .10 atmospheres.
In group 1, a 0.014 in. Doppler-tipped wire was used as
the angioplasty guidewire. Baseline and hyperemic flow
velocity measurements were obtained before and after an-
gioplasty at the same guidewire location. Coronary velocity
reserve was defined as the ratio between maximal velocity
during hyperemia induced by an intracoronary bolus of
adenosine (12 mg for the right coronary artery and 18 mg for
the left coronary artery) and rest velocity as previously
described (4,8). The Doppler velocity signal was continu-
ously recorded on videotape for off-line analysis.
All patients were on aspirin (250 mg daily) and received
intravenous heparin 100 IU/kg at the onset of the proce-
dure. Patients in whom a stent was placed additionally
received ticlopidine 500 mg daily for four weeks after the
procedure.
Quantitative angiography. All measurements were made
after intracoronary injection of 1 mg of linsidomine (except
in patients in whom systolic blood pressure was
,100 mm Hg).
All cinefilms were analyzed by an independent core
laboratory, blinded to all clinical and Doppler data (Hoˆpital
Pitie´-Salpe`trie`re, Paris, France). Two orthogonal views of
the target lesion at each step of the procedure (pre-PTCA,
after balloon angioplasty and after stenting) were selected
for off-line quantitative analysis. Computer-assisted quan-
titative angiographic analysis was performed using a vali-
dated automatic edge-detection algorithm, as previously
described (9). A 6F guiding catheter free of contrast was
used for calibration. The minimal luminal diameter (MLD)
and reference diameter proximal to the lesion were mea-
sured as previously described (9). The inter- and intraob-
server variations for QCA DS were 9 6 12% and 7 6 14%,
respectively.
Six months after the procedure, all patients were evalu-
ated clinically and underwent repeat coronary angiography,
unless it had been clinically required after the initial three
months, with repeat QCA measurements, duplicating the
views and methods of the initial assessment.
End points. The primary end point was the final MLD at
the target site measured by QCA at six-month follow-up.
Secondary end points were: 1) the binary restenosis rate
defined as $50% residual stenosis at the six-month angio-
graphic follow-up, and 2) the incidence of major adverse
cardiac events (death, myocardial infarction, revasculariza-
tion of the target lesion) at the six-month follow-up.
Myocardial infarction was defined as two or more of the
three following criteria: new Q waves, chest pain of
.30 min duration, elevation of creatinine phosphokinase to
more than two-fold the normal level associated with ele-
vated CK-MB fraction within the 24 h after angioplasty.
The protocol was reviewed and approved by the Ethics
Committee of the Hoˆpital Boucicaut (Paris, France).
Statistical analysis. Analysis was based on intent to treat
with comparison of the six-month MLD of group 1
(provisional stenting) and group 2 (systematic stenting).
Sample size was calculated, using two-sided testing, an
alpha risk of 0.05 and a beta risk of 0.20. Assuming a
difference between groups of at least 0.22 mm and a
six-month MLD of 1.9 6 0.6 mm based on previous
quantitative angiographic studies of stents in similar patient
populations, 117 patients were required per group (2,10,11).
Assuming a 10% dropout rate, the sample size required was
251 patients.
All quantitative values were given as mean 6 standard
deviation (SD). Comparisons between groups used unpaired
t tests for quantitative variables and chi-square test and
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CVR 5 coronary velocity reserve
DEBATE 5 Doppler End Points Balloon Angioplasty
Trial Europe
DESTINI 5 Doppler End Point Stenting International
Investigation Coronary Flow Reserve
DS 5 diameter stenosis
MLD 5 minimal lumen diameter
PTCA 5 percutaneous transluminal coronary
angioplasty
QCA 5 quantitative coronary angiography
SD 5 standard deviation
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Fisher’s exact test for qualitative variables, as appropriate.
All p values were two-tailed. Data acquisition and analyses
were performed using the SAS statistical software (Proc
Access of SAS) in order to compare double data acquisition
(Proc Compare, SAS). All differences detected were re-
viewed with the investigators and the Critical Event Com-
mittee and performed using the SAS statistical software
(SAS 6.12, SAS Institute Inc., SAS Cary, North Carolina).
RESULTS
Characteristics of patients. Between November 1996 and
April 1998, 253 patients were enrolled in the trial by 17
french hospitals: 126 patients were randomly assigned to
provisional stenting (group 1) and 127 to systematic stent-
ing (group 2). After randomization, two patients (group 2)
were excluded from analysis for major protocol violations
(one for elective PTCA of two lesion sites on the same
vessel and one for recent myocardial infarction). The base-
line characteristics of the patients are displayed in Tables 1
and 2. Most of the patients (64.5% of the total cohort)
underwent PTCA after unstable angina. The procedural
results are displayed in Table 3.
In-hospital outcome. In group 1, Doppler signals were
acquired in all patients but one (99.2%) in whom no correct
signal could be obtained. There was no complication related
to the Doppler device. Sixty-five patients (51.6%) fulfilled
both the angiographic and Doppler criteria for successful
angioplasty after balloon PTCA and did not receive a stent.
Conversely, 61 patients (48.4%) needed a stent either as a
bail-out measure (17 patients, 13.5%) or due to failure to
meet the CVR and QCA criteria for success after balloon
angioplasty alone (44 patients, 34.9%). Among these 44
patients, Doppler was involved in the decision to stent in
75%: 20 (45.5%) for failure to fulfil the CVR criteria alone
and 13 (29.5%) for failure to fulfill both CVR and QCA
criteria; 11 (25%) failed to fulfil the QCA criteria alone. In
group 1, there was no significant difference in heart rate and
arterial pressure before and after PTCA (124.2 6
22.7 mm Hg vs. 125.6 6 23.3 mm Hg; p 5 0.81 and
67.0 6 15.2 vs. 66.1 6 11.9, p 5 0.77).
Table 1. Baseline Clinical Characteristics
Group 1
n 5 126
Group 2
n 5 125 p Value
Age (yrs) 59.3 6 11 60.6 6 10.3 0.33
Systolic blood pressure (mm Hg) 131 6 19 134 6 21 0.17
Diastolic blood pressure (mm Hg) 75 6 10 74 6 10 0.46
Heart rate (beats/min) 65 6 12 64 6 10 0.34
Male gender 102 (81.0%) 104 (83.2%) 0.84
Prior myocardial infarction 15 (11.9%) 15 (12.0%) 0.98
Prior bypass surgery 1 (0.8%) 2 (1.6%) 0.99
Hypercholesterolemia .6.5 mmol/L 59 (46.8%) 60 (48.0%) 0.90
Hypertension 46 (36.5%) 55 (44.0%) 0.35
Smoking (previous or current) 66 (52.4%) 64 (51.2%) 0.89
Diabetes mellitus 16 (12.7%) 23 (18.4%) 0.25
Family history of coronary artery disease 33 (26.2%) 45 (36.0%) 0.16
Indication for PTCA 0.44
Stable angina 44 (34.9%) 35 (28.0%)
Unstable angina 78 (61.9%) 84 (67.2%)
Silent ischemia 4 (3.2%) 6 (4.8%)
PTCA 5 percutaneous transluminal coronary angioplasty.
Values are mean 6 SD.
Table 2. Baseline Angiographic Characteristics
Group 1
n 5 126
Group 2
n 5 125 p Value
Target vessel 0.09
Left anterior descending coronary artery 54 (42.9%) 70 (56.0%)
Left circumflex 29 (23.0%) 19 (15.2%)
Right coronary artery 43 (34.1%) 36 (28.8%)
ACC/AHA lesion type 0.94
A 40 (32.3%) 43 (34.4%)
B 81 (65.3%) 79 (63.2%)
C 3 (2.4%) 3 (2.4%)
Reference diameter (mm) 3.09 6 0.57 3.07 6 0.49 0.84
Lesion length (mm) 10.0 6 4.5 9.7 6 3.7 0.57
Lesion diameter stenosis (%) 75.3 6 10.9 76.6 6 9.8 0.31
Left ventricular ejection fraction (angiographic) (%) 66.8 6 8.8 65.6 6 8.6 0.31
ACC/AHA 5 American College of Cardiology/American Heart Association lesion classification (24).
Values are mean 6 SD.
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In group 2, stent placement was successfully performed in
100% although two patients required another stent than the
PS153, due to failure of the device to cross the lesion.
Ultimately, 48.4% of the patients in group 1 received a stent
as opposed to 100% in group 2 (p , 0.0001).
The baseline MLD and DS were comparable between
groups 1 and 2 (Table 3). There was a major reduction in
the degree of lesion stenosis in both groups; as expected, this
was more marked in group 2. The larger balloon size and
balloon/artery ratio in group 1 reflected attempts to opti-
mize results of balloon angioplasty.
During the in-hospital stay, major adverse cardiac events
were identical between groups: there were two myocardial
infarctions (1.6%) in each group, no death and no need for
target vessel revascularization (bypass surgery, re-PTCA).
In group 1 there was an increase in CVR after the
procedure in both unstented patients (from 1.7 6 0.7 to
3.0 6 0.7, p , 0.0001) and stented patients (from 1.6 6 0.6
to 2.5 6 0.9, p , 0.0001).
Six-month follow-up. Clinical follow-up was obtained in
all the patients. Repeat coronary angiography was per-
formed in 93.6% of the patients in group 1 and 92.1% in
group 2, on average 25.5 6 8.8 weeks after the initial
procedure. At follow-up, there were three deaths in group 2,
one due to sudden death, one secondary to myocardial
infarction, one occurring after elective coronary artery by-
pass surgery. There was one myocardial infarction in group
1 and two in group 2. The six-month angiographic results
are summarized in Table 4. The final angiographic outcome
was similar between groups, both in terms of MLD, DS and
late loss. The binary restenosis rate was similar between
groups (27.1% vs. 21.4%, in groups 1 and 2 respectively, p 5
0.37). This was consistent with the lack of difference in
terms of target lesion revascularization between groups
(15.1% vs. 14.4% in groups 1 and 2, respectively, p 5 0.89).
However, the study was not powered for detecting mean-
ingful clinical differences. Among patients with restenosis,
13/32 (40.6%) in group 1 but 100% (25/25) in group 2 had
in-stent restenosis (p , 0.01).
DISCUSSION
The strategy of systematic stenting did not appear to
provide significantly superior angiographic results at six
months compared with a strategy of provisional stenting
guided by QCA and CVR assessment. The latter strategy
appeared safe because it was not associated with an excess of
adverse clinical events and achieved similar six-month
results while obviating the need for stenting in 51.6% of the
patients (without suppressing it) although the study was
powered for detecting only angiographic differences. Need
for stenting was comparable with DEBATE II and
DESTINI trials (55% and 45%, respectively [6,7]). Conse-
quently, there was much less in-stent restenosis in the
Table 3. Procedural Results
Group 1
n 5 126
Group 2
n 5 125 p Value
Procedure duration (min) 74 6 30 48 6 22 0.0001
Baseline MLD (mm) 0.75 6 0.40 0.71 6 0.30 0.29
Final MLD (mm) 2.50 6 0.53 2.64 6 0.43 0.027
Acute gain (mm) 1.75 6 0.59 1.93 6 0.51 0.009
Baseline diameter stenosis (%) 75.3 6 10.9 76.6 6 9.8 0.31
Final stenosis (%) 18.8 6 11.2 13.8 6 9.9 0.0003
Maximal balloon inflation
pressure (atm)
10.2 6 3.1 12.6 6 2.4 0.0001
Balloon size (mm) 3.3 6 0.40 3.2 6 0.40 0.005
Balloon/artery ratio 1.11 6 0.23 1.05 6 0.19 0.037
Stent placement: n (%) 61 (48.4%) 125 (100%) 0.0001
atm 5 atmosphere; MLD 5 minimal lumen diameter.
Values are mean 6 SD.
Table 4. Six-month Angiographic Results
Group 1
n 5 118
Group 2
n 5 117 p Value
Patients with follow-up angiography 118 (93.6%) 117 (93.6%) 1
Time to follow-up angiography (weeks) 25.3 6 7.9 25.8 6 9.6 0.60
Reference diameter (mm) 3.02 6 0.50 3.03 6 0.47 0.83
Follow-up MLD (mm) 1.90 6 0.79 1.99 6 0.70 0.39
Late loss (mm) 0.58 6 0.75 0.67 6 0.74 0.37
Net gain (mm) 1.15 6 0.85 1.27 6 0.75 0.25
Loss index 20.35 6 0.51 20.34 6 0.37 0.76
Follow-up diameter stenosis (%) 36.4 6 23.1 33.8 6 21.3 0.36
Restenosis (DS . 50%): n (%) 32 (27.1%) 25 (21.4%) 0.37
DS 5 diameter stenosis; MLD 5 minimal lumen diameter.
Values are mean 6 SD.
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provisional stenting group than there was in the systematic
stent group (13 vs. 25 patients, that is, 40.6 vs. 100% of the
restenotic patients, p , 0.01).
Restenosis occurring after PTCA remains the major
limitation of interventional cardiology (12,13). While stents
have been shown to reduce its incidence in selected lesion
subsets, a new problem has emerged with the high recur-
rence rate of in-stent restenosis when treated with repeat
percutaneous coronary intervention (14). In fact, in-stent
restenosis appears refractory to conventional balloon angio-
plasty techniques, leading to research into radiation therapy,
gene therapy and local drug delivery as possible therapeutic
avenues to prevent its recurrence (15–18). Therefore, it is
worthwhile to be able to identify patients with satisfactory
PTCA results who may derive no benefit from systematic
stenting.
Strategies of provisional stenting. Real-time assessment
of the immediate outcome of percutaneous intervention
remains difficult because angiography has important limita-
tions (19). Even after plain balloon angioplasty, the majority
of patients do not require repeat revascularization and would
derive no benefit from additional stenting. This was the
message proposed by DEBATE-I, an observational study
including only nonstented patients; patients with a good
distal CVR and minimal residual stenosis after balloon
angioplasty had a low six-month restenosis rate and a
clinical follow-up similar to those of stented patients from
contemporary randomized trials (1,2,4). Subsequently, it
has been shown that, after successful conventional balloon
angioplasty, optimization maneuvers, such as stenting or
using bigger balloons, were able to improve CVR even when
the initial angiographic result of PTCA appeared satisfac-
tory (6). This suggests that Doppler assessment of CVR is
able to detect angiographically invisible alterations of the
vessel, which impact on long-term outcome despite CVR
self limitations (that is, left ventricular hypertrophy, cardio-
myopathy, presence of collaterals).
This provides the background for provisional stenting.
This study is the first to evaluate this strategy using
physiological assessment of the PTCA result on top of
QCA. The results appear to validate the concept since
provisional stenting achieved an MLD at six months similar
to systematic stenting. It is reassuring that the attempt to
achieve a satisfactory CVR according to predefined criteria
in the provisional stenting group, reflected by the higher
balloon size and balloon/artery ratio, was not associated
with an increased incidence of periprocedural complications
or a high rate of bailout stenting. As expected, the imme-
diate angiographic result appeared more favorable with
systematic stenting than with provisional stenting. How-
ever, increased late loss with systematic stenting ultimately
resulted in similar clinical outcome in the DESTINI trial
and angiographic outcome at six months in both groups (7).
Study limitations. The MLD was selected as the primary
end point, which allows the study of restenosis using a
continuous parameter rather than a dichotomic one, better
reflecting the biologic phenomenon. However, the trial was
not powered to detect meaningful differences in binary
restenosis or clinical outcomes. By design, this pragmatic
trial could not be blinded. However, possible biases in
evaluation of the results were limited by angiographic core
laboratory analysis. Despite randomization, there may have
been imbalances in patients characteristics, including non-
significant differences in left anterior descending artery
distribution. This study was designed for an angiographic
primary end point. From an angiographic point of view,
restenosis is independent of the location of the dilated
lesion. Thus, this particular point has a minimal impact on
the interpretation of the primary end point of the study. The
trend towards more frequent left anterior descending artery
lesions in the systematic stenting group could have favored
the provisional stenting group in terms of clinical follow-up,
which was a secondary end point of our study. Mean
pressure for stent deployment was 12 6 1.9 atmospheres. In
a recent study evaluating the respective interest of intracoro-
nary ultrasound and intracoronary pressure measurements to
optimize stent placement, the best results were obtained
with a mean inflation pressure of 11.8 atmospheres (20).
We can, thus, consider that the quality of stent placement
would not gain any benefit from either IVUS or pressure
guidance in this study. This study did not aim to evaluate
the cost/effectiveness of the respective strategy. However, it
has to be pointed out that the cost of the catheters and
equipment for CVR added to 48.4% stenting was obviously
superior than the cost of 100% stenting since a Doppler
catheter was as expensive as a stent. The procedure time of
the guided strategy has to be mentioned, namely with regard
to possibly longer fluoroscopic exposure. The systematic
angiographic follow-up may have increased the target lesion
revascularization rates although these are similar to those
reported by the DESTINI trial, which did not have angio-
graphic follow-up. In addition, any potential bias derived
from the practice of systematic reangiography at six months
must have affected both groups in a similar way. The
relatively short follow-up may have missed some differences
in outcome related to the high propensity for recurrence of
in-stent restenosis (14,21,22). However, since there was
more in-stent restenosis in group 2 than in group 1,
presumably more late events would occur in group 2.
Therefore, this short follow-up period would tend to un-
derestimate the benefit of provisional stenting. The criteria
used for patient and lesion selection were somewhat restric-
tive and, therefore, any extrapolation of the results to a
population at higher risk and more severe lesions may be
questioned. Nevertheless, it is noteworthy that the vast
majority of patients had an unstable clinical presentation,
and angiographic selection criteria were similar to those of
contemporary stent trials (17,23).
This study evaluated the strategy of provisional stenting
guided by anatomic and functional criteria. It appears that
systematic stenting does not provide superior angiographic
results at six months as compared with provisional stenting.
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There is a dramatically lower rate of in-stent restenosis
occurring after provisional stenting compared with system-
atic stenting (40.6% vs. 100%), which may impact the
long-term clinical outcome.
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